Related Experiment Video
Updated: Jul 13, 2026
10:04
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
Published on: December 2, 2022
End-stage liver disease in a state prison population
Jacques Baillargeon1, Roger D Soloway, David Paar
1Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555, USA. jbaillar@utmb.edu
Annals of Epidemiology
|August 11, 2007
Summary
End-stage liver disease (ESLD) is more prevalent and deadly in Texas prisons, particularly among those with HIV and hepatitis C virus (HCV) coinfection. Expanding HCV treatment and prevention is crucial for this vulnerable population.
Area of Science:
- Hepatology
- Public Health
- Correctional Medicine
Background:
- Epidemiological data on end-stage liver disease (ESLD) within US correctional populations remain scarce.
- Understanding ESLD prevalence and outcomes in incarcerated individuals is critical for public health initiatives.
Purpose of the Study:
- To investigate the prevalence, mortality rates, and clinical characteristics of ESLD.
- To analyze ESLD epidemiology within the Texas prison system, the second largest in the US.
Main Methods:
- A retrospective analysis of medical and demographic data was conducted.
- Data from 370,511 incarcerated individuals over a 3.5-year period were examined.
Main Results:
- ESLD was diagnosed in 484 inmates (131/100,000), with 213 (57/100,000) succumbing to the disease.
- Elevated ESLD prevalence and mortality were observed in Hispanic individuals, those aged 30-50 or over 50, and those with HIV, hepatitis C virus (HCV), or coinfection.
Conclusions:
- ESLD mortality in the Texas prison population is approximately threefold higher than in the general population.
- High rates of HCV and HIV/HCV coinfection contribute to increased ESLD mortality among prisoners.
- Enhanced HCV treatment and prevention strategies are imperative for correctional healthcare systems to address the significant burden of ESLD.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:24Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...